A sensitive liquid chromatography–electrospray ionization–mass spectrometry (LC-ESI-MS) method was established and validated for the determination of glycyrrhizin in dog plasma. After treatment with methanol to precipitate proteins, plasma samples were analyzed on a reversed-phase C18 (ODS) column with a mobile phase of methanol:1% formic acid solution (75:25, v/v). MS determination was performed using negative electrospray ionization (negative ESI) in the selected ion monitoring mode. Glycyrrhizin was monitored at the m/z 821 channel and the internal standard (gliquidone) at the m/z 526 channel. The calibration curve was linear over the range from 0.05 μg mL−1 to 10 μg mL−1 with a correlation coefficient above 0.99. This method was successfully applied to the pharmacokinetic studies in beagle dogs. The absolute bioavailability of glycyrrhizin in beagle dogs was 3.24%.
ShibataS., “A drug over the millennia: Pharmacognosy, chemistry, and pharmacology of licorice”, Yakugaku Zasshi120, 849 (2000).
2.
ShinY.BaeE.LeeB.LeeS.H.KimJ.A.KimY.KimD., “In vitro and in vivo antiallergic effects of Glycyrrhiza glabra and its components”, Planta Med.73, 257 (2007). doi: 10.1055/s-2007-967126
3.
AlyA.M.Al-AlousiL.SalemH.A., “Licorice: A possible anti-inflammatory and anti-ulcer drug”, AAPS Pharmscitech.6, E74 (2005). doi: 10.1208/pt060113
4.
DavisE.A.MorrisD.J., “Medicinal uses of licorice through the millennia: The good and plenty of it”, Mol. Cell. Endocrinol.78, 1 (1991).
5.
WeiJ.NiJ.WuT.ChenX.DuanX.LiuG.YiaoJ.WangQ.ZhenJ.ZhouL., “A systematic review of Chinese medicinal herbs for acute bronchitis”, J. Altern. Complem. Med.12, 159 (2006). doi: 10.1089/acm.2006.12.159
6.
LuperS., “A review of plants used in the treatment of liver disease: Part two”, Altern. Med. Rev.4, 178 (1999).
7.
FioreC.EisenhutM.RagazziE.ZanchinG.ArmaniniD., “A history of the therapeutic use of liquorice in Europe”, J. Ethnopharmacol.99, 317 (2005). doi: 10.1016/j.jep.2005.04.015
8.
ShenX.XiaoP.LiuC., “Research and application of radix glycyrrhizae”, Asian J. Pharmacodyn. Pharmacokinet.7, 181 (2007).
9.
IsbruckerR.A.BurdockG.A., “Risk and safety assessment on the consumption of licorice root (Glycyrrhiza sp.), its extract and powder as a food ingredient, with emphasis on the pharmacology and toxicology of glycyrrhizin”, Regul. Toxicol. Pharm.46, 167 (2006). doi: 10.1016/j.yrtph.2006.06.002
10.
AkamatsuH.KomuraJ.AsadaY.NiwaY., “Mechanism of anti-inflammatory action of glycyrrhizin: Effect on neutrophil functions including reactive oxygen species generation”, Planta Med.57, 119 (1991). doi: 10.1055/s-2006-960045
11.
ItoM.SatoA.HirabayashiK.TanabeF.ShigetaS.BabaM.ClercqE.D.NakashimaH.YamamotoN., “Mechanism of inhibitory effect of glycyrrhizin on replication of human immunodeficiency virus (HIV)”, Antiviral Res.10, 289 (1998). doi: 10.1016/0166-3542(88)90047-2
12.
AslM.N.HosseinzadehH., “Review of pharmacological effects of Glycyrrhiza sp. and its bioactive compounds”, Phytother. Res.22, 709 (2008). doi: 10.1002/ptr.2362
13.
ZhaiD.ZhaoY.ChenX.GuoJ.HeH.YuQ.YangJ.DaveyA.K.WangJ., “Protective effect of glycyrrhizin, glycyrrhetic acid and matrine on acute cholestasis induced by alpha-naphthyl isothiocyanate in rats”, Planta Med.73, 128 (2007). doi: 10.1055/s-2006-957067
14.
ZhaoY.ZhaiD.ChenX.HeH.LuQ.YuQ., “Protective effect of glycyrrhizin and matrine on acute vanishing bile duct syndrome induced by alpha naphthylisothiocyanate in rats”, Hepat. Res.37, 143 (2007). doi: 10.1111/j.1872-034X.2007.00019.x
15.
SuzukiH.OhtaY.TakinoT.FujisawaK.HirayamaC., “Effects of glycyrrhizin on biochemical tests in patients with chronic hepatitis—double blind trial”, Asian Med. J.26, 423 (1983).
16.
HattoriM.SakamotoT.KobashiK.NambaT., “Metabolism of glycyrrhizin by human intestinal flora”, Planta Med.48, 38 (1983) doi: 10.1055/s-2007-969875
17.
HattoriM.SakamotoT.YamagishiT.SakamotoK.KonishiK.KobashiK.NambaT., “Metabolism of glycyrrhizin by human intestinal flora. II. Isolation and characterization of human intestinal bacteria capable of metabolizing glycyrrhizin and related compounds”, Chem. Pharm. Bull.33, 210 (1985).
18.
LuY.ZhuJ.ChenX.LiN.FuF.HeJ.WangG.ZhangL.ZhengY.QiuZ.YuX.HanD.WuL., “Identification of human UDP-glucuronosyltransferase isoforms responsible for the glucuronidation of glycyrrhetinic acid”, Drug Metab. Pharmacokinet.24, 523 (2009). doi: 10.2133/dmpk.24.523
19.
ZhangX.Y.WuR.J.ChenJ.AnD.K., “Determination of glycyrrhizin and its metabolite glycyrrhetinic acid in rabbit plasma by high-performance liquid chromatography after oral administration of licorzin”, J. Chromatogr. B: Biomedical Sciences and Applications495, 343 (1989). doi: 10.1016/S0378-4347(00)82643-2
20.
LinZ.P.J.QiuS.X.WufuerA.ShumL., “Simultaneous determination of glycyrrhizin, a marker component in radix glycyrrhizae, and its major metabolite glycyrrhetic acid in human plasma by LC-MS/MS”, J. Chromatogr. B814, 201 (2005). doi: 10.1016/j.jchromb.2004.10.026
21.
KogaK.OhmachiK.KawashimaS.TakadaK.MurakamiM., “Determination of 18α-glycyrrhizin and 18β-glycyrrhizin in dog plasma by high-performance liquid chromatography”, J. Chromatogr. B738, 165 (2000). doi: 10.1016/S0378-4347(99)00490-9
22.
ShibataN.OhnoT.ShimokawaT.HuZ.YoshikawaY.KogaK.MurakamiM.TakadaK., “Application of pressure-controlled colon delivery capsule to oral administration of glycyrrhizin in dogs”, J. Pharm. Pharmacol.53, 441 (2001). doi: 10.1211/0022357011775730
